Javelin Pharmaceuticals has announced the preliminary results of a randomized, placebo- controlled pilot Phase II study with intranasal Ketamine in 60 patients with moderate-to-severe pain following
bunion surgery.
Treatment with intranasal Ketamine was well-tolerated. There were no unexpected or serious adverse events related to the study drug. Local adverse events associated with nasal administration (throat irritation, oral discomfort, oral hypoaesthesia, rhinorrhea) were more common in the intranasal
Ketamine treatment groups. General adverse events that were reported more frequently for the active drug treatment group included dizziness, dysgeusia and somnolence.
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
Devicemakers Comment on FDA’s Approach to Machine Learning for SaMD
GE Healthcare urged the agency to consider an expedited pathway for software changes.
Genentech Wins Accelerated Approval for Chemoimmunotherapy
The agency previously granted Polivy breakthrough therapy, priority review and orphan drug status.
